Dasatinib
Brand: Sprycel (US/EU) / Dasatinib (IN/BD)
Anticancer
BCR-ABL Tyrosine Kinase Inhibitor
Pharmacokinetics
| Half-life | 4 hours |
| Tmax | 1 h |
| Protein Binding | 96 % |
| Volume of Distribution | 2.5 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Best absorption in acidic stomach. Avoid PPIs/H2 blockers. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Myelosuppression, pleural effusion, pulmonary hypertension
Contraindications:
Severe hepatic impairment
Precautions:
Chest X-ray if dyspnea; manage effusion with steroids/diuretics